Zobrazeno 1 - 10
of 165
pro vyhledávání: '"Laurence Booth"'
Publikováno v:
European Medical Journal, Pp 127-133 (2022)
Neratinib was developed as an irreversible catalytic inhibitor of ERBB2, which also acts to inhibit ERBB1 and ERBB4. Neratinib is U.S. Food and Drug Administration (FDA)-approved as a neo-adjuvant therapy for use in HER2+ breast cancer. More recently
Externí odkaz:
https://doaj.org/article/cdacbc83be84411aa1963794eeb48ed3
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
GZ17-6.02 is undergoing clinical evaluation in solid tumors and lymphoma. We defined the biology of GZ17-6.02 in prostate cancer cells and determined whether it interacted with the PARP1 inhibitor olaparib to enhance tumor cell killing. GZ17-6.02 int
Externí odkaz:
https://doaj.org/article/3573b92758b84eecb29e3a3dfd3deca6
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
We have extended our analyses of HDAC inhibitor biology in sarcoma. The multi-kinase inhibitor axitinib interacted with multiple HDAC inhibitors to kill sarcoma cells. Axitinib and HDAC inhibitors interacted in a greater than additive fashion to inac
Externí odkaz:
https://doaj.org/article/5ff1f49d5e3c41198e86b3f06d7ce526
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
We determined the molecular mechanisms by which the novel therapeutic GZ17-6.02 killed non-small cell lung cancer (NSCLC) cells. Erlotinib, afatinib, and osimertinib interacted with GZ17-6.02 to kill NSCLC cells expressing mutant EGFR proteins. GZ17-
Externí odkaz:
https://doaj.org/article/837468e93d0e46f1a9917b694f144e3f
Publikováno v:
European Medical Journal Oncology, Vol 7, Iss 1, Pp 81-89 (2019)
It has been stated that developing a drug that can attack mutated RAS proteins is ‘the Holy Grail’ of cancer therapeutics. Through a series of unexpected findings, the authors discovered that the irreversible epidermal growth factor receptor 1/2/
Externí odkaz:
https://doaj.org/article/b4ba450397304f08ba11f3c47539ee3b
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
We defined the lethal interaction between the novel therapeutic GZ17-6.02 and the standard of care combination of the MEK1/2 inhibitor trametinib and the B-RAF inhibitor dabrafenib in PDX isolates of cutaneous melanoma expressing a mutant B-RAF V600E
Externí odkaz:
https://doaj.org/article/6aa3d464e9f1493298d91bd326a49302
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Externí odkaz:
https://doaj.org/article/d050e1aeeb2f47a9bb8acc2cd1c8d522
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
GZ17-6.02 (602) is presently under phase I clinical evaluation (NCT03775525). We defined the mechanisms by which it interacted with a standard of care therapeutic doxorubicin to kill sarcoma cells. Doxorubicin and 602 interacted to rapidly activate A
Externí odkaz:
https://doaj.org/article/b87b8c46f31548329f746ae9e97f01dc
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Externí odkaz:
https://doaj.org/article/d9e04d01b2ed4c839ca8f0cf7278e1af
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Previously we demonstrated that the multiple sclerosis drug dimethyl fumarate (DMF) and its plasma breakdown product MMF could interact with chemotherapeutic agents to kill both GBM cells and activated microglia. The trial NCT02337426 demonstrated th
Externí odkaz:
https://doaj.org/article/417ae753fd424a9f9a2248b690dd7c36